Generative Artificial Intelligence (AI) In Pharmaceutical
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Generative Artificial Intelligence (AI) In Pharmaceutical Market Size Growth Forecast: What to Expect by 2025?
The market size of generative artificial intelligence (AI) in the pharmaceutical sector has seen an exponential increase in recent years. It’s predicted to surge from $1.85 billion in 2024 to $2.43 billion in 2025, reflecting a compound annual growth rate (CAGR) of 31.3%. Factors contributing to this growth during the historical period include enhanced computational power, the emergence of big data in healthcare and pharmaceutical domains, increased investments in research and development, better quality and integration of data, and the proliferation of cloud computing.
How Will the Generative Artificial Intelligence (AI) In Pharmaceutical Market Size Evolve and Grow by 2029?
The market size for generative artificial intelligence (AI) in the pharmaceutical sector is projected to experience significant expansion in the upcoming years. It is anticipated to reach a value of $7.16 billion by 2029, with a compound annual growth rate (CAGR) of 31.0%. This predicted growth during the projected period can be credited to several factors including the emphasis on early detection of diseases, regulatory endorsement, and guidelines, enhanced computational abilities, an increase in drug development costs, and an upsurge in data accessibility. The forecast period may also observe dominant trends such as the integration of blockchain and AI, advanced data integration, improved disease diagnosis, automation in drug repurposing, and optimized real-time clinical trials.
View the full report here:
https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-pharmaceutical-global-market-report
What Drivers Are Propelling the Growth of Generative Artificial Intelligence (AI) In Pharmaceutical Market Forward?
The surging emphasis on tailored healthcare is anticipated to accelerate the expansion of generative artificial intelligence (AI) within the pharmaceutical industry. Personalized medicine customizes medical care based on each patient’s unique characteristics, requirements, and preferences, considering their genetic, environmental, and lifestyle aspects. The increased focus on this area is due to advances in genetic studies and technology, permitting more accurate and efficient treatments adapted for individual patients. Personalized medicine applies generative AI in pharmaceuticals to create individualized drug therapies, enhancing treatment success and patients’ health results. For example, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the US, reported that the FDA authorized 16 novel personalized treatments for patients with rare diseases in 2023, a significant increase from six in 2022. Thus, the escalating concentration on personalized medicine is paving the way for the growth of generative AI within the pharmaceutical marketplace.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19474&type=smp
Which Emerging Trends Are Transforming the Generative Artificial Intelligence (AI) In Pharmaceutical Market in 2025?
In the generative AI pharmaceutical market, significant players are creating innovative products, such as AI healthcare microservices, to expedite drug discovery procedures. These microservices are modular and cloud-based, utilizing AI to enhance healthcare operations ranging from drug discovery and medical imaging to diagnostics. For example, Nvidia Corporation, a leading technology firm in the US, rolled out generative AI microservices in March 2024. This offering incorporates optimized NIM AI models and workflows with APIs tailored for developing cloud-centric applications. It enables advanced imaging, natural language and speech recognition, as well as digital biology functions. The primary tools integrated, including Parabricks, MONAI, NeMo, Riva, and Metropolis, are available as CUDA-X microservices, assisting in improving workflows in drug discovery and genomics.
What Are the Key Segments in the Generative Artificial Intelligence (AI) In Pharmaceutical Market?
The generative artificial intelligence (AI) in pharmaceutical market covered in this report is segmented –
1) By Type: Small Molecule, Large Molecule
2) By Technology: Deep Learning, Natural Language Processing, Querying Method, Context-Aware Processing, Other Technologies
3) By Application: Clinical Trial Research, Drug Discovery, Research And Development, Other Applications
Subsegments:
1) By Small Molecule: Drug Discovery And Design, Lead Optimization For Small Molecule Compounds, Predictive Modeling For Pharmacokinetics And Toxicity, Virtual Screening Of Compound Libraries, Personalized Medicine Approaches For Small Molecule Therapies
2) By Large Molecule: Biologics Discovery And Development, Monoclonal Antibody Design, Protein Engineering And Optimization, Vaccine Development And Optimization, Predictive Models For Biopharmaceutical Efficacy And Safety.
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19474&type=smp
Who Are the Key Players Shaping the Generative Artificial Intelligence (AI) In Pharmaceutical Market’s Competitive Landscape?
Major companies operating in the generative artificial intelligence (AI) in pharmaceutical market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Fujitsu Limited, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., NVIDIA Corporation, Conduent Incorporated, XtalPi Inc., Insilico Medicine Inc., Numerate Inc., Atomwise Inc., BenevolentAI Limited
What Geographic Markets Are Powering Growth in the Generative Artificial Intelligence (AI) In Pharmaceutical Market?
North America was the largest region in the generative artificial intelligence (AI) in the pharmaceutical market in 2024. The regions covered in the generative artificial intelligence (AI) in pharmaceutical market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19474
“This Report Supports:
1.Business Leaders & Investors – To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers – To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators – To track industry developments and align regulatory frameworks.
4.Consultants & Analysts – To support market entry, expansion strategies, and client advisory work.”
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
